Mounjaro, a novel medication, is generating considerable interest within the glycemic care landscape. This dual-action injectable therapy combines a incretin receptor stimulator with a glucose-regulated insulinotropic hormone , offering a potentially considerable benefit in glucose control for individuals facing T2D . Early clinical findings sug… Read More